SGX To Focus On BCR-ABL Partnership After Discontinuing Troxatyl Trial
Phase II/III trial in AML patients halted due to low response rates, but SGX says it will focus on a collaboration with Novartis.
Phase II/III trial in AML patients halted due to low response rates, but SGX says it will focus on a collaboration with Novartis.